COPYRIGHT © DIGITAL JOURNAL INC. Sitemaps: XML / News. Digital Journal is not responsible for the content of external sites. Read more about our external linking
Data Bridge Market research has a newly released expansive study titled “Global Apixaban Market” which guarantees you will remain better informed than your competition. This study provides a broader perspective of the marketplace with its comprehensive market insights and analysis which eases survival and succeeding in the market. A complete overview of the industry has been presented via this Intercom Devices report which considers various aspects of product definition, market segmentation, and the existing retailer landscape.
The market is projected to observe major growth during the forecast period. Apixaban is generally indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. The recommended dose of Eliquis is 5mg orally twice a day. Apixaban is available in the market in both capsule and tablet form. The development of advanced anticoagulants increases the demand and provides numerous options to patients and healthcare professionals.
Data Bridge Market Research analyses a growth rate in the global apixaban market in the forecast period 2023-2030. The expected CAGR of the global apixaban market tends to be around 5.70% in the mentioned forecast period. The market was valued at USD 1,765.8 million in 2022 and would grow to USD 2,908.17 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Download PDF Sample Report (Including Graphs, Charts, and List of Figures) @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-apixaban-market&Shri
Apixaban is an FDA-approved anticoagulant which is used for the treatment of venous thromboembolic events that forms inside a vein. Venous thromboembolic events (VTE) can occur without any typical symptoms or warning signs. The common symptoms associated with either deep vein thrombosis (DVT) or either pulmonary embolism (PE) are chest pain, pain in the calf, redness or noticeable discoloration spots, swelling in the ankle or foot, and others.
Fundamental Aim of this Market Report
Opportunities
There has been an increasing development in the research end front, creating many opportunities for market growth. For instance, the ARISTOTLE trial showed that apixaban is superior to warfarin in decreasing stroke and systemic embolism in patients with atrial fibrillation. Pfizer collaborated with Bristol-Myers Squibb to develop and commercialize apixaban; the alliance strengthens both companies to expand potential in cardiovascular drug development and commercialization.
The apixaban is the third non-vitamin K antagonist oral anticoagulant used for clinical practice. The regular dose of apixaban is highly effective in decreasing thromboembolic events compared to warfarin. In December 2019, the US FDA approved the first generics of apixaban tablets, and FDA’s generic drug program enables access to cost-effective and high-quality drugs
Restraints/Challenges
Several adverse effects of apixaban, such as the increased risk of thrombotic events after premature discontinuation and bleeding, are projected to hamper this drug’s usage. This, in turn, is estimated to adversely affect the market’s growth.
To treat conditions that are rare, several times, all treatments are not available, particularly in underdeveloped countries. Severe patients need to be treated with advanced techniques, but these are sometimes unavailable in hospitals and clinics. Thus, it hampers market growth.
This global apixaban market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global apixaban market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Key players operating in the global apixaban market include:
To Gain More Insights into the Market Analysis, Browse the Summary of the Research Report@ https://www.databridgemarketresearch.com/reports/global-apixaban-market?Shri
Apixaban Market Scope
Dosage Form
End-Users
Distribution Channel
Key highlights of this Market report:
What benefits does the DBMR study is going to provide?
Table of Contents:
Continued…
Browse Detailed Summary of Research Report with TOC: https://www.databridgemarketresearch.com/toc/?dbmr=global-apixaban-market&Shri
Key Benefits of the Report:
Top DBMR Healthcare Reports:
https://www.databridgemarketresearch.com/reports/global-cardasil-treatment-market?Shri
https://www.databridgemarketresearch.com/reports/global-aestheticcosmetic-lasers-market?Shri
https://www.databridgemarketresearch.com/reports/global-yeast-infection-market?Shri
About Data Bridge Market Research:
An absolute way to forecast what future holds is to comprehend the trend today!
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.
Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.
Contact Us:-
Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Email:- corporatesales@databridgemarketresearch.com